Drug Search Results
More Filters [+]

Cefotiam

Alternative Names: cefotiam, ceradon
Latest Update: 2017-02-07
Latest Update Note: Clinical Trial Update

Product Description

Cefotiam is a third-generation, semi-synthetic, beta-lactam cephalosporin antibiotic with antibacterial activity. Cefotiam binds to penicillin-binding proteins (PBPs), transpeptidases that are responsible for crosslinking of peptidoglycan. By preventing crosslinking of peptidoglycan, cell wall integrity is lost and cell wall synthesis is halted. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Cefotiam)

Mechanisms of Action: Cell Wall Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: China | Egypt | France | Germany | Indonesia | Ireland | Korea | Peru | Philippines | Taiwan | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Beijing Boshi Antai Technology Development Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cefotiam

Countries in Clinic: China, Unknown Location

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Other

Phase 1: Respiratory Tract Infections|Urinary Tract Infections

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CTR20150519

P3

Recruiting

Other

None

CTR20170642

P1

Not yet recruiting

Urinary Tract Infections|Respiratory Tract Infections

None

Recent News Events

Date

Type

Title